Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant 17.75% surge in open interest (OI) in its derivatives segment, signalling heightened market activity and evolving investor positioning. Despite a modest 0.16% gain in the stock price, the underlying dynamics suggest a complex interplay of bullish and cautious bets as the stock trades close to its 52-week high.

Aurobindo Pharma Ltd. has witnessed a significant 15.96% surge in open interest in its derivatives segment, signalling heightened market activity and evolving investor positioning. Despite trading close to its 52-week high, the stock’s recent underperformance relative to its sector and the broader Sensex suggests a complex interplay of bullish and cautious sentiment among traders.

Aurobindo Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a slight dip in the share price, the stock continues to demonstrate resilience against broader market declines, supported by a complex interplay of technical indicators such as MACD, RSI, Bollinger Bands, and moving averages.

Aurobindo Pharma Ltd. has witnessed a significant 27.8% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest 1.07% decline in its share price on 23 Mar 2026, the pharmaceutical giant’s futures and options volumes suggest a complex interplay of bullish and cautious bets amid a broader sector downturn.

Aurobindo Pharma Ltd. has witnessed a significant 21.4% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest decline in its share price, the pharmaceutical mid-cap continues to trade near its 52-week high, outperforming its sector amid a broader market downturn.

Aurobindo Pharma Ltd. has witnessed a significant 18.7% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest 1.04% decline in the stock price on 23 Mar 2026, the pharmaceutical company’s futures and options volumes have surged, reflecting a complex interplay of bullish and bearish bets amid a broader sector downturn.

Aurobindo Pharma Ltd. has witnessed a notable surge in open interest in its derivatives segment, with an 11.76% increase signalling heightened market activity and shifting investor positioning. Despite a slight dip in the stock price, the pharmaceutical company’s futures and options volumes suggest a complex interplay of bullish and cautious bets amid broader sector weakness.

Aurobindo Pharma Ltd. has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underscored by positive signals from key technical indicators such as the MACD and moving averages, despite mixed readings from other momentum oscillators. The stock’s recent price action, combined with its relative performance against the Sensex, suggests a cautiously optimistic outlook for investors in the Pharmaceuticals & Biotechnology sector.

Aurobindo Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish trend. Despite a day-on-day decline of 1.53% to close at ₹1,267.70 on 19 Mar 2026, the stock’s broader technical indicators reveal a complex interplay of signals that investors should carefully analyse before making decisions.

Aurobindo Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underscored by improvements in key technical indicators such as the MACD, moving averages, and Bollinger Bands, signalling renewed investor interest despite broader market headwinds.

Aurobindo Pharma Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 16 March 2026. This adjustment reflects a nuanced reassessment across four critical parameters: quality, valuation, financial trend, and technicals. While the company continues to demonstrate solid fundamentals and consistent returns, evolving market dynamics and technical indicators have prompted a more cautious stance.

Aurobindo Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a 1.95% decline in the latest trading session, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, Bollinger Bands, and moving averages, suggesting cautious optimism for investors.

Aurobindo Pharma Ltd. reached a significant milestone today by hitting a new 52-week high of Rs.1319.6, marking a continuation of its strong upward momentum amid a challenging broader market environment.

Aurobindo Pharma Ltd. has reached a significant milestone by hitting a new 52-week high of Rs.1312, marking a strong rally in the Pharmaceuticals & Biotechnology sector amid a broadly negative market backdrop.

Aurobindo Pharma Ltd. has been upgraded from a Hold to a Buy rating, reflecting significant improvements across technical indicators, financial metrics, valuation, and overall quality. The upgrade, effective from 10 March 2026, follows a robust quarter and a bullish technical outlook, positioning the pharmaceutical company favourably against its peers and broader market benchmarks.

Aurobindo Pharma Ltd. has demonstrated a significant shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is supported by key technical indicators such as MACD, Bollinger Bands, and moving averages, signalling a positive outlook for the pharmaceutical giant amid a challenging market environment.

Aurobindo Pharma Ltd. reached a significant milestone on 10 Mar 2026, hitting a new 52-week high of Rs.1279.8, marking a notable surge in the Pharmaceuticals & Biotechnology sector amid mixed market conditions.

Aurobindo Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 March 2026, providing investors with an up-to-date perspective on its performance and outlook.